Article
Nanoscience & Nanotechnology
Yi-Qing Chen, Wen-Ting Zhu, Cai-Yan Lin, Zhong-Wen Yuan, Zhen-Hua Li, Peng-Ke Yan
Summary: This study successfully constructed a liposome delivery system for rapamycin to enhance its efficacy in treating colorectal cancer. The rapamycin liposomes showed superior antitumor effects compared to free rapamycin both in vitro and in vivo, and were able to synergistically enhance the efficacy of 5-FU in colorectal cancer via the Akt/mTOR and P53 pathways.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Review
Oncology
Shiekhah M. Alzahrani, Huda A. Al Doghaither, Ayat B. Al-Ghafari, Peter N. Pushparaj
Summary: Although 5-FU-based chemotherapy is widely used for colorectal cancer, it has limitations. Capecitabine, a prodrug of 5-FU, was developed to overcome these drawbacks and achieve more convenient therapy. This review compares the properties and efficacy of 5-FU therapy and capecitabine therapy, including drug metabolism, cellular mechanisms, safety, and tolerability. Future research should explore the combination of capecitabine with novel drugs to inhibit tumor initiation, progression, and metastasis.
Article
Oncology
Amy de Haar-Holleman, Lisa M. C. van Hoogstraten, Maarten C. C. M. Hulshof, Metin Tascilar, Katharin Bruck, Richard P. Meijer, J. Alfred Witjes, Lambertus A. Kiemeney, Katja K. H. Aben
Summary: This study compared the toxicity, overall survival (OS), and disease-free survival (DFS) between oral capecitabine and intravenous 5-fluorouracil (5-FU) in chemoradiotherapy for muscle-invasive bladder cancer (MIBC) patients. There was no significant difference in adverse events, 2-year OS, and 2-year DFS between the two regimens. Capecitabine-based CRT may be considered as an alternative to a 5-FU-based regimen.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Plant Sciences
Kaichun Wang, Wei Liu, Qinfen Xu, Chao Gu, Daode Hu
Summary: This study found that Tenacissoside G (TG) exhibited dose-dependent growth inhibitory activity and cell cycle arrest induction in colorectal cancer cells, enhancing the anticancer effects of 5-fluorouracil (5-FU). The synergistic effects may be attributed to increased activation of caspase cascade, enhancement of DNA damage, and induction of p53 phosphorylation at Serine 46.
Article
Clinical Neurology
Valentine Perrain, Kevin Bihan, Flavie Bompaire, Caroline Houillier, Fanny Jomier, Delphine Leclercq, Sandrine Combret, Julien Mahe, Damien Ricard, Giulia Berzero, Dimitri Psimaras
Summary: 5-Fluorouracil and its prodrug capecitabine can lead to acute leukoencephalopathies with transient splenial lesions, which are generally reversible upon discontinuation of the drug. Resuming the agent may be feasible in selected cases, after exclusion of dihydropyrimidine dehydrogenase deficiency, if expected benefits outweigh the risks.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Oncology
Hao Yang, Sha Xie, Beibei Liang, Qiqi Tang, Huanchen Liu, Dongliang Wang, Gang Huang
Summary: In this study, high expression of IDH1 in human colorectal cancer tissues was found to indicate high-grade tumors. Exosomal IDH1 derived from 5FU-resistant cells enhanced resistance to 5FU in sensitive cells by decreasing the level of IDH1-mediated NADPH, potentially acting as a driver of chemoresistance in colorectal cancer.
Article
Chemistry, Applied
Mostafa Yusefi, Michiele Soon Lee-Kiun, Kamyar Shameli, Sin-Yeang Teow, Roshafima Rasit Ali, Kit-Kim Siew, Hui-Yin Chan, Magdelyn Mei-Theng Wong, Wei-Ling Lim, Kamil Kuca
Summary: The study developed a multifunctional magnetic cellulose nanocomposite MC/5-FU, demonstrating potential as a low-cost drug carrier for colorectal cancer treatments.
CARBOHYDRATE POLYMERS
(2021)
Article
Oncology
Shuohui Dong, Songhan Li, Xiaoyan Wang, Shuo Liang, Wenjie Zhang, Linchuan Li, Qian Xu, Bowen Shi, Zhiqiang Cheng, Xiang Zhang, Mingwei Zhong, Guangyong Zhang, Sanyuan Hu
Summary: This study found that the high expression of CD147 is associated with decreased chemosensitivity and unfavorable prognosis in colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU). CD147 regulates glycolipid metabolism by upregulating HIF-1 alpha-mediated glycolysis and attenuating PPAR alpha-mediated fatty acid oxidation, resulting in 5-FU resistance in CRC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Mengmeng Wang, Xuqin Guo, Man Yang, Yawen Zhang, Fanyi Meng, Yinshuang Chen, Mengxi Chen, Tian Qiu, Jiawei Li, Zhi Li, Qi Zhang, Fang Xu, Haiyang Zhang, Weipeng Wang
Summary: Atosiban potentiates the antitumor effect of 5-Fu by enhancing its inhibitory effect on MSS-type CRC cells and eliminating 5-Fu-induced GATA3 expression.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Pathology
Yu-Ling Qu, Xiao-Li Liu, Shan-Yu Zhao, Xue-Feng Zhai
Summary: This study found that SPOCK1 is upregulated in 5-FU-resistant CRC cells and that knockdown of SPOCK1 increases their sensitivity to 5-FU. Conversely, overexpression of SPOCK1 enhances CRC cell resistance to 5-FU and reduces cell apoptosis.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Review
Biochemistry & Molecular Biology
Eleni A. Karatrasoglou, Maria Dimou, Alexia Piperidou, Eleftheria Lakiotaki, Penelope Korkolopoulou, Theodoros P. Vassilakopoulos
Summary: This review focuses on discussing the oncogenic mechanisms of the PI3K/v-akt/mTOR pathway in B cell non-Hodgkin lymphoma (NHL), and summarizes the clinical applications of mTOR inhibitors in B cell NHLs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, Research & Experimental
Simona Salerno, Anders Stahlberg, Andre Holdfeldt, Elinor Bexe Lindskog, Goran Landberg
Summary: Colorectal cancer is a common diagnosis worldwide, with many patients not responding to standard chemotherapy. This study used patient-derived scaffolds to investigate how individual patient-specific microenvironments influence the chemotherapy response in colorectal cancer. The findings suggest that tumor microenvironment can influence drug resistance and potential disease relapse, providing insights for optimized precision medicine in colorectal cancer treatment.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Sareh Kamran, Ajantha Sinniah, Zamri Chik, Mohammed Abdullah Alshawsh
Summary: The combination of 5-FU and diosmetin has a synergistic effect against colorectal cancer cells, reducing the toxicity of 5-FU while enhancing its anticancer efficacy. This combination induces apoptosis and interrupts cell mitosis to achieve its anticancer effects.
Article
Medicine, Research & Experimental
Rinad A. Algehani, Raefa Abou Khouzam, Gehan A. Hegazy, Aliaa A. Alamoudi, Ali M. El-Halawany, Riham S. El Dine, Ghada A. Ajabnoor, Fahad A. Al-Abbasi, Mohammed A. Baghdadi, Ibrahim Elsayed, Masao Hattori, Ahmed M. Al-Abd
Summary: A synergistic effect in terms of anticancer properties was observed when colossolactone-G was combined with 5-FU and GCB, influencing both apoptosis and autophagic cell death mechanisms.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Pharmacology & Pharmacy
Neda Khosravi, Vahid Khaze Shahgoli, Mohammad Amini, Sahar Safaei, Ahad Mokhtarzadeh, Behzad Mansoori, Afshin Derakhshani, Amir Baghbanzadeh, Behzad Baradaran
Summary: The study demonstrated that Nanog knockdown in combination with 5-FU treatment effectively suppressed the pathophysiological processes induced by Nanog in CRC cells, including reducing migration and enhancing drug sensitivity.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Oncology
Ari Vanderwalde, David Spetzler, Nianqing Xiao, Zoran Gatalica, John Marshall
Article
Oncology
Michael J. Pishvaian, Hongkun Wang, Aiwu Ruth He, Jimmy J. Hwang, Brandon G. Smaglo, Sunnie S. Kim, Benjamin A. Weinberg, Louis M. Weiner, John L. Marshall, Jonathan R. Brody
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Michael Cerniglia, Joanne Xiu, Axel Grothey, Michael J. Pishvaian, Yasmine Baca, Jimmy J. Hwang, John L. Marshall, Ari M. VanderWalde, Anthony F. Shields, Heinz-Josef Lenz, W. Michael Korn, Mohamed Salem, Philip A. Philip, Richard M. Goldberg, Jia Zeng, Sunnie S. Kim
Summary: This study comprehensively assesses the prevalence of HR-DDR mutations in gastroesophageal adenocarcinomas and squamous cell carcinomas, and finds that a subset of these tumors carry HR-DDR mutations that are correlated with immune biomarkers. Understanding the relationship between HR-DDR mutations and immune biomarkers may help develop more effective immunotherapy strategies.
MOLECULAR CANCER THERAPEUTICS
(2022)
Review
Oncology
John L. Marshall, Beth N. Peshkin, Takayuki Yoshino, Jakob Vowinckel, Havard E. Danielsen, Gerry Melino, Ioannis Tsamardinos, Christian Haudenschild, David J. Kerr, Carlos Sampaio, Sun Young Rha, Kevin T. FitzGerald, Eric C. Holland, David Gallagher, Jesus Garcia-Foncillas, Hartmut Juhl
Summary: This paper discusses the development and importance of multiomics in clinical practice, highlighting the knowledge gap within the medical community and urging physicians to actively adapt and prepare for this new era.